U.S. FDA Approves Dupilumab (Dupixent, Sanofi & Regeneron) for CSU
Add chronic spontaneous urticaria (CSU) to the list of U.S. Food and Drug Administration (FDA) approvals for dupilumab (Dupixent, Sanofi & Regeneron). Dupilumab is now FDA-approved for its latest indication: treating patients aged 12+ years with uncontrolled CSU who remain symptomatic despite H1-antihistamines. Dupilumab is first targeted therapy for CSU in a decade. This approval […]